Clinical and imaging outcomes of different phenotypes of axial spondyloarthritis : 5-year analysis of the DESIR cohort
Copyright © 2024 Elsevier Inc. All rights reserved..
OBJECTIVES: To compare the long-term outcomes of three phenotypes of axial SpA (axSpA).
METHODS: Patients with a clinical diagnosis of axSpA from the DESIR cohort were grouped into three phenotypes at baseline: 'Pure axSpA' ('Axial'), 'axSpA with peripheral signs' ('IBP+Peripheral') and 'axSpA at risk' ('At risk') by latent class analysis. Clinical and imaging data were collected up to 5 years. Clinical outcomes, measured in each visit, included disability (BASFI) and quality of life (QoL; SF36). Imaging outcomes included inflammatory and structural lesions on MRI and radiographs of spine and SIJ. The association between phenotype membership at baseline and each outcome was tested in multivariable GEE models.
RESULTS: In total, 576 patients with axSpA were included. 'At risk' patients had worse disability and QoL than 'Axial' patients over time. For instance, 'At risk' patients had on average 0.4 more points in BASFI over time than 'Axial' patients [β (95 % CI): 0.4 (0.2; 0.7)]. This difference was mostly noted in female patients who were HLA-B27 positive. In addition, the difference between the 'At risk' and 'Axial' phenotypes was higher in patients receiving bDMARDs than in those not (β=0.6 vs 0.5), since BASFI improved more in 'Axial' (∆BASFI: -1.3) than in 'At risk' (∆BASFI: -0.9) treated patients. There were no differences in disability and QoL between 'Axial' and 'IBP+Peripheral' patients. Imaging outcomes were worse in the 'Axial' phenotype than in the others over time.
CONCLUSION: Patients with 'axSpA at risk' show worse self-reported outcomes over time and are less likely to benefit from anti-inflammatory treatment than those with a classical axSpA phenotype.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Seminars in arthritis and rheumatism - 66(2024) vom: 02. März, Seite 152424 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sepriano, Alexandre [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 13.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.semarthrit.2024.152424 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369688244 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369688244 | ||
| 003 | DE-627 | ||
| 005 | 20240315000208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.semarthrit.2024.152424 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM369688244 | ||
| 035 | |a (NLM)38479110 | ||
| 035 | |a (PII)S0049-0172(24)00064-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sepriano, Alexandre |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and imaging outcomes of different phenotypes of axial spondyloarthritis |b 5-year analysis of the DESIR cohort |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVES: To compare the long-term outcomes of three phenotypes of axial SpA (axSpA) | ||
| 520 | |a METHODS: Patients with a clinical diagnosis of axSpA from the DESIR cohort were grouped into three phenotypes at baseline: 'Pure axSpA' ('Axial'), 'axSpA with peripheral signs' ('IBP+Peripheral') and 'axSpA at risk' ('At risk') by latent class analysis. Clinical and imaging data were collected up to 5 years. Clinical outcomes, measured in each visit, included disability (BASFI) and quality of life (QoL; SF36). Imaging outcomes included inflammatory and structural lesions on MRI and radiographs of spine and SIJ. The association between phenotype membership at baseline and each outcome was tested in multivariable GEE models | ||
| 520 | |a RESULTS: In total, 576 patients with axSpA were included. 'At risk' patients had worse disability and QoL than 'Axial' patients over time. For instance, 'At risk' patients had on average 0.4 more points in BASFI over time than 'Axial' patients [β (95 % CI): 0.4 (0.2; 0.7)]. This difference was mostly noted in female patients who were HLA-B27 positive. In addition, the difference between the 'At risk' and 'Axial' phenotypes was higher in patients receiving bDMARDs than in those not (β=0.6 vs 0.5), since BASFI improved more in 'Axial' (∆BASFI: -1.3) than in 'At risk' (∆BASFI: -0.9) treated patients. There were no differences in disability and QoL between 'Axial' and 'IBP+Peripheral' patients. Imaging outcomes were worse in the 'Axial' phenotype than in the others over time | ||
| 520 | |a CONCLUSION: Patients with 'axSpA at risk' show worse self-reported outcomes over time and are less likely to benefit from anti-inflammatory treatment than those with a classical axSpA phenotype | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Axial spondyloarthritis | |
| 650 | 4 | |a Phenotypes | |
| 650 | 4 | |a Prognosis | |
| 700 | 1 | |a Ramiro, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a van der Heijde, Désirée |e verfasserin |4 aut | |
| 700 | 1 | |a Moltó, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Gaujoux-Viala, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Dougados, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Landewé, Robert |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in arthritis and rheumatism |d 1971 |g 66(2024) vom: 02. März, Seite 152424 |w (DE-627)NLM000215643 |x 1532-866X |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2024 |g day:02 |g month:03 |g pages:152424 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semarthrit.2024.152424 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2024 |b 02 |c 03 |h 152424 | ||